Skip to main content
. Author manuscript; available in PMC: 2019 Dec 1.
Published in final edited form as: Pediatr Blood Cancer. 2018 Aug 27;65(12):e27420. doi: 10.1002/pbc.27420

Table 1:

Study Demographics

Genotype Patients (%)
N=108
Admissions (%)
N=236
Hb SS/Sβ0 thalassemia 80 (74) 182 (77)
Hb SC 24 (22) 45 (19)
HbSβ+ thalassemia 4 (4) 9 (4)
SCD Modifying Therapy
Hydroxyurea 53 (49) 122 (52)
HU/Transfusion 10 (9) 50 (21)
No therapy 45 (42) 64 (27)
VOC Frequency
< 3 admissions 87 (81) 109 (46)
≥ 3 admissions 21 (19) 127 (54)